Format

Send to

Choose Destination
Sci Rep. 2017 Dec 20;7(1):17917. doi: 10.1038/s41598-017-17733-z.

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome.

Author information

1
Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
2
Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
3
Department of Medical Oncology, Institut Curie, Paris, France.
4
Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
5
Department of Medical Oncology, Gustave Roussy, Villejuif, France.
6
Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.
7
Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.
8
Department of Medical Oncology, Centre René Gauducheau, St. Herblain, Saint-Herblain, France.
9
Department of Medical Oncology, Hôpital Jean Minjoz, Besançon, France.
10
Department of Pathology, Centre Léon Bérard, Lyon, France.
11
Université Claude Bernard, Lyon, France.
12
Department of Medical Oncology, Centre Léon Bérard, Lyon, France. philippe.cassier@lyon.unicancer.fr.

Abstract

Ewing's sarcoma family of tumors (EFTs) is a group of rare and aggressive tumors. Data on EFTs in patients (pts) ≥ 50 years are limited and these pts are often not eligible for clinical trials. Some, but not all, studies have reported inferior outcome for older pts with EFTs. We conducted an IRB-approved retrospective analysis among centers of the French Sarcoma Group on pts diagnosed with EFTs at age ≥50 between 2000 and 2012. Clinical features, treatment modality and outcomes were analyzed. Seventy-seven pts were identified, including 36 females (46.8%) and the median age at diagnosis was 56 years (range: 50-86). The primary tumor was located in soft tissue in 59 pts (76.6%). Fifty-six pts (72.7%) had localized disease, among them 49 (87.5%) received chemotherapy in addition to local therapy. Their estimated 3-yr OS and event-free survival (EFS) rates were respectively 73.3% and 62.2%. Recurrence occurred in 43 pts. The estimated 3-yr OS rate was 37% in pts with metastatic disease at presentation. EFTs in pts ≥50 years are more likely to originate from soft tissue and their outcomes appear to be worse than that of younger pts treated with modern protocols.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center